CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Phase 3 Completed 32 enrolled Janssen-Ortho Inc., Canada

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTAÂ® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD).

Timeline

Start: 2005-03
Primary completion: —
Completion: 2005-12

Publications

Results Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906X154132.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	18 mg	Oral
Subject	Methylphenidate	Small molecule	36 mg	Oral
Subject	Methylphenidate	Small molecule	54 mg	Oral
Subject	Methylphenidate	Small molecule	72 mg	Oral

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Summary

Timeline

Publications

Drugs

Indications